VEGFA and diabetic macular edema: Center-involving diabetic macular edema (DME) is a leading cause of vision loss amongdiabetic patients in developed countries.1 In the past 2 decades, intravitreal vascular endothelial growth factor (VEGF)inhibitors have emerged as a first-line treatment, with efficacy based on visualacuity (VA) measurements and structural improvement on optical coherence tomography (OCT).2 The monitoring of clinical and anatomic factors, such as OCT central macularthickness (CMT), in conjunction with VA is often used to guide decision-making indetermining the treatment frequency for patients with DME.3